VERADIGM INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2016-11-03: Form 8-K; Period of report 2016-11-03; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2016-11-01: Form 8-K; Period of report 2016-10-27; Description 2.01 Completion of Acquisition or Disposition of Assets.
- 2016-08-04: Form 8-K; Period of report 2016-08-04; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2016-07-06: Form 8-K; Period of report 2016-07-06; Description 7.01 Regulation FD Disclosure.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2016-11-03 | 8-K | 2016-11-03 | 2.02 Results of Operations and Financial Condition | 2.02 On November 3, 2016, Allscripts Healthcare Solutions, Inc. (the “Company”) issued a press release regarding the Company’s financial results for the three and nine months ended September 30, 2016. | f8k_110316.htm |
| 2016-11-01 | 8-K | 2016-10-27 | 2.01 Completion of Acquisition or Disposition of Assets | mdrx-8k_20161027.htm | |
| 2016-08-04 | 8-K | 2016-08-04 | 2.02 Results of Operations and Financial Condition | 2.02 On August 4, 2016, Allscripts Healthcare Solutions, Inc. (the “Company”) issued a press release regarding the Company’s financial results for the three and six months ended June 30, 2016. | f8k_080416.htm |
| 2016-07-06 | 8-K | 2016-07-06 | 7.01 Regulation FD Disclosure | mdrx-8k_20160705.htm | |
| 2016-07-05 | 8-K | 2016-06-30 | 3.02 Unregistered Sales of Equity Securities | 3.02 On June 30, 2016, Allscripts Healthcare Solutions, Inc. (the “Company”) issued to a commercial partner, as part of an overall commercial relationship, unregistered warrants (“Warrants”) to purchase (A) 900,000 shares of Company common stock, par value $0.01 per share (“Common Stock”), at a price per share of $12.47, (B) 1,000,000 shares of Common Stock at a price per share of $14.34, and (C) 1,100,000 shares of Common Stock at a price per share of $15.59, in each case subject to customary anti-dilution adjustments. | mdrx-8k_20160630.htm |
| 2016-07-05 | 8-K/A | 2016-04-19 | 9.01 Financial Statements and Exhibits | 9.01 (a) Financial statements of businesses acquired. | mdrx-8ka_20160419.htm |
| 2016-05-25 | 8-K | 2016-05-24 | 5.07 Submission of Matters to a Vote of Security Holders | d189495d8k.htm | |
| 2016-05-05 | 8-K | 2016-05-05 | 2.02 Results of Operations and Financial Condition | 2.02 On May 5, 2016, Allscripts Healthcare Solutions, Inc. (the “Company”) issued a press release regarding the Company’s financial results for the three months ended March 31, 2016. | f8k_050516.htm |
| 2016-04-25 | 8-K | 2016-04-19 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 In connection with the closing of the transactions under the Contribution Agreement, on April 19, 2016, a wholly-owned subsidiary of Allscripts (together with any permitted transferees, the “Allscripts Members”) and GI (together with any permitted transferees, the “GI Members”), entered into an Amended and Restated Limited Liability Company Agreement of the JV (the “Operating Agreement”). 2.01 The disclosure contained above under “Introductory Note” in this Current Report on Form 8-K is incorporated herein by reference. 2.03 The disclosure contained above in Item 1.01 of this Current Report on Form 8-K under the heading “JV Credit Facilities” is incorporated herein by reference. | mdrx-8k_20160419.htm |
| 2016-04-11 | 8-K | 2016-04-05 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 5, 2016, Anita V. Pramoda, a member of the Board of Directors (the “Board”) of Allscripts Healthcare Solutions, Inc. (the “Company”), informed the Company that she will not stand for re-election when her term expires at the Company’s 2016 Annual Meeting of Stockholders. | mdrx-8k_20160405.htm |
| 2016-03-23 | 8-K | 2016-03-20 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; 8.01 Other Events | 1.01 On March 20, 2016, Allscripts Healthcare Solutions, Inc., a Delaware corporation (“Allscripts”), entered into a Contribution and Investment Agreement (the “Contribution Agreement”) with GI Netsmart Holdings LLC, a Delaware limited liability company (“GI”), Andrews Henderson LLC, a Delaware limited liability company (“Henderson”), and Nathan Holding LLC, a Delaware limited liability company (the “JV”). 7.01 On March 23, 2016, Allscripts issued a press release announcing the transactions described above under Item 1.01 of this Current Report on Form 8-K. A copy of Allscripts’ press release is attached hereto as Exhibit 99.1. 8.01 The disclosure under the heading “JV Agreement” in Item 1.01 of this Current Report on Form 8-K is incorporated by reference herein. | d138126d8k.htm |
| 2016-02-18 | 8-K | 2016-02-18 | 2.02 Results of Operations and Financial Condition | 2.02 On February 18, 2016, Allscripts Healthcare Solutions, Inc. (the “Company”) issued a press release regarding the Company’s financial results for the three and twelve months ended December 31, 2015. | f8k_021816.htm |
| 2016-02-02 | 8-K | 2016-01-29 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 On February 2, 2016, Allscripts Healthcare Solutions, Inc. (the “Company”) announced that Melinda D. Whittington has been appointed as Senior Vice President, Finance. 7.01 On February 2, 2016, the Company issued a press release announcing Ms. Whittington’s appointment. | mdrx-8k_20160129.htm |
| 2016-01-12 | 8-K | 2016-01-12 | 7.01 Regulation FD Disclosure | 7.01 On January 12, 2016, Allscripts Healthcare Solutions, Inc. (the “Company”) will present at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, California. | mdrx-8k_20160112.htm |